Outcomes of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer

Concurrent chemoradiotherapy (CRT) based on cisplatin is recognized as the current standard treatment for locally advanced cervical cancer. The of cancer has reached a plateau in last 20 years. Previous studies have proven that epidermal growth factor receptor correlated with chemo- and radioresistance failure. Hence, purpose this study was to investigate efficacy safety icotinib combined CRT Eligibility criteria included patients treated radiotherapy department Taizhou Central Hospital Zhejiang Province stage IIB IIIB cancers who had not received anti-tumor before performance status 0 2. Patients were given 125 mg three times day 6 weeks, which one week start (500 centigrays 28 fractions) chemotherapy (40 mg/m2 administered weekly 3-5 cycles). There 29 completed I+CRT treatment, it tolerated well. median follow-up time 50 months 27 (93.10%) achieved complete responses. 5-year cumulative overall survival rate disease-free 58.4% 60.9%, respectively. safe effective As far we know, first report targeted therapy chemoradiotherapy.